S. Burke

发表

Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.

S. Badylak, A. Simmons, J. Henkin, 1991, Thrombosis research.

Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.

J. Henkin, D. Davidson, S. Burke, 1996, Thrombosis research.

Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.

C. Wegner, B. Cox, G. Reinhart, 2002, American journal of physiology. Heart and circulatory physiology.

Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine.

C. Wegner, B. Cox, S. Burke, 2000, Journal of cardiovascular pharmacology.

Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion.

S. Burke, R. Nelson, 1997, Journal of cardiovascular pharmacology.

New developments in thrombolytic therapy.

S. Badylak, J. Henkin, A. Sasahara, 1992, Advances in pharmacology.

Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs.

J. Henkin, R. Klabunde, S. Burke, 1990, Thrombosis research.

Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.

C. Wegner, B. Dayton, J. Wessale, 1997, Journal of cardiovascular pharmacology.

Recombinant Pro-Urokinase Requires Heparin for Optimal Clot Lysis and Restoration of Blood Flow in a Canine Femoral Artery Thrombosis Model

J. Henkin, S. Burke, N. Lubbers, 1993, Thrombosis and Haemostasis.

Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.

R. B. Credo, S. Burke, R. Credo, 1995, Journal of vascular and interventional radiology : JVIR.

Profile of Recombinant Pro-urokinase Given by Intraarterial versus Intravenous Routes of Administration in a Canine Thrombosis Model

C. Wegner, B. Cox, S. Burke, 1999, Thrombosis and Haemostasis.

Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor.

A. M. Lefer, A. Lefer, S. Burke, 1983, British journal of clinical pharmacology.

Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischemia in dogs

A. M. Lefer, A. Lefer, S. Burke, 1982, Basic Research in Cardiology.

Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death.

A. Lefer, S. Burke, J. Smith, 1983, Thrombosis research.

Antagonism of platelet aggregation by 13-azaprostanoic acid in acute myocardial ischemia and sudden death.

A. M. Lefer, A. Lefer, D. Roth, 1983, Thrombosis research.

Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues

A. M. Lefer, A. Lefer, S. Burke, 1983, British journal of pharmacology.

Preservation of ischemic myocardial tissue with an antagonist of vasoconstrictor eicosanoids.

A. M. Lefer, A. Lefer, S. Burke, 1984, Canadian journal of physiology and pharmacology.

Protection of Ischemic Cat Myocardium By CGS‐13080, a Selective Potent Thromboxane A2 Synthesis Inhibitor

A. M. Lefer, A. Lefer, S. Burke, 1983, Journal of cardiovascular pharmacology.

The Protective Effect of Heparin in a Dog Model of Rethrombosis Following Pharmacologic Thrombolysis

S. Badylak, A. Simmons, J. Henkin, 1990, Thrombosis and Haemostasis.

Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.

D. B. Evans, I. Sircar, S. Burke, 1989, Journal of medicinal chemistry.

Zotarolimus (ABT-578) eluting stents.

R. Kuntz, L. Schwartz, S. Burke, 2006, Advanced drug delivery reviews.

Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.

I. Sircar, S. Burke, H. Barth, 1992, Journal of medicinal chemistry.

Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues.

I. Sircar, M. Cain, S. Burke, 1986, Journal of medicinal chemistry.

Comparison of Dose Regimens for the Administration of Recombinant Pro-urokinase in a Canine Thrombosis Model

J. Henkin, S. Burke, N. Lubbers, 1997, Thrombosis and Haemostasis.

Continuous Measurements of ATP Secretion in Vivo

A. M. Lefer, A. Lefer, S. Burke, 2004, Pharmaceutical Research.

Protective actions of ibuprofen in arachidonate-induced sudden death.

A. Lefer, D. Roth, S. Burke, 1983, Pharmacology.

Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks.

R. Schwartz, A. García-Touchard, S. Burke, 2006, European heart journal.

Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model.

R. Schwartz, D. Holmes, A. Lerman, 1998, Circulation.

Evaluation of tissue perfusion in a rat model of hind‐limb muscle ischemia using dynamic contrast‐enhanced magnetic resonance imaging

J. Segreti, Yanping Luo, V. Hradil, 2002, Journal of magnetic resonance imaging : JMRI.

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.

C. Wegner, G. Hsieh, S. Burke, 1999, Journal of cardiovascular pharmacology.

Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.

A. M. Lefer, D. Lefer, A. Lefer, 1983, Archives internationales de pharmacodynamie et de therapie.

Oral bimoclomol elevates heat shock protein 70 and reduces myocardial infarct size in rats.

G. Diaz, C. Wegner, B. Cox, 2002, European journal of pharmacology.